Sysmex Corporation (TYO:6869)

Japan flag Japan · Delayed Price · Currency is JPY
1,379.00
-21.00 (-1.50%)
Apr 28, 2026, 3:30 PM JST
-48.17%
Market Cap 857.03B
Revenue (ttm) 502.95B
Net Income (ttm) 44.75B
Shares Out 621.48M
EPS (ttm) 71.77
PE Ratio 19.21
Forward PE 19.20
Dividend 36.00 (2.57%)
Ex-Dividend Date Mar 30, 2026
Volume 3,911,300
Average Volume 3,050,910
Open 1,430.00
Previous Close 1,400.00
Day's Range 1,373.00 - 1,432.00
52-Week Range 1,268.00 - 2,710.50
Beta 0.65
RSI 43.84
Earnings Date May 14, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]

Sector Healthcare
Founded 1968
Employees 10,533
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 6869
Full Company Profile

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial Statements

News

Sysmex Earnings Call Transcript: Q2 2026

First half results saw declines in revenue and profit due to Japan's ecosystem transition, inventory devaluation, and a challenging Chinese market, while overseas regions excluding China performed well. Full-year forecasts were revised down, but growth is expected in emerging markets and new business areas.

6 months ago - Transcripts